European journal of preventive cardiology · 2026
A remote booster program to attenuate sedentary behaviour in patients with coronary artery disease: a randomized controlled trial.
СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kroesen Sophie H, van Bakel Bram M A, de Bruin Marijn, Pisters Martijn F, Ortega Francisco B, Hopman Maria T E, Thijssen Dick H J, Bakker Esmée A, Eijsvogels Thijs M H
Аннотация
AIMS: Sedentary time (ST) can be reduced in patients with coronary artery disease (CAD) during cardiac rehabilitation (CR), but most patients relapse to sedentarism within months. We examined the effectiveness of a 3-week remote booster intervention on ST changes in CAD patients.
METHODS AND RESULTS: Coronary artery disease patients who previously [2.0 (1.9-2.2) years] completed CR were included in this randomized controlled trial (1:1, stratified for gender). All participants received usual care, whereas booster participants additionally received a 3-week remote behavioural change intervention. The primary outcome was the change in accelerometer-derived ST from baseline to post-intervention and secondary outcomes included changes in sedentary behaviour and physical activity (PA) characteristics. A baseline constrained linear mixed model on an intention-to-treat basis was used. Participants (19% female, booster: n = 21, control: n = 21) were 69 [63-75] years old. Greater decreases in ST {-1.3 [95% confidence interval (CI): -2.0; -0.6] vs. -0.1 (95% CI: -0.8; 0.6) h/day, p-interaction = 0.012} and number of prolonged sedentary bouts [-1.1 (95% CI: -1.6; -0.6) vs. 0.2 (95% CI: -0.3; 0.7) bouts/day, p-interaction < 0.001] in combination with larger increases in light PA [+1.1 (95% CI: + 0.5; + 1.8) vs. +0.2 (95% CI: -0.4; + 0.8) h/day, p-interaction = 0.030] were found for the booster vs. control group. Changes in moderate-to-vigorous PA (p-interaction = 0.13) and step count (p-interaction = 0.18) did not differ between groups.
CONCLUSION: The remote booster program effectively reduced ST and increased light PA in CAD patients. These findings highlight the potential to change physical (in)activity behaviour of patients beyond completion of traditional CR programs.
TRIAL REGISTRATION: NCT06038188 (ClinicalTrials.gov).
METHODS AND RESULTS: Coronary artery disease patients who previously [2.0 (1.9-2.2) years] completed CR were included in this randomized controlled trial (1:1, stratified for gender). All participants received usual care, whereas booster participants additionally received a 3-week remote behavioural change intervention. The primary outcome was the change in accelerometer-derived ST from baseline to post-intervention and secondary outcomes included changes in sedentary behaviour and physical activity (PA) characteristics. A baseline constrained linear mixed model on an intention-to-treat basis was used. Participants (19% female, booster: n = 21, control: n = 21) were 69 [63-75] years old. Greater decreases in ST {-1.3 [95% confidence interval (CI): -2.0; -0.6] vs. -0.1 (95% CI: -0.8; 0.6) h/day, p-interaction = 0.012} and number of prolonged sedentary bouts [-1.1 (95% CI: -1.6; -0.6) vs. 0.2 (95% CI: -0.3; 0.7) bouts/day, p-interaction < 0.001] in combination with larger increases in light PA [+1.1 (95% CI: + 0.5; + 1.8) vs. +0.2 (95% CI: -0.4; + 0.8) h/day, p-interaction = 0.030] were found for the booster vs. control group. Changes in moderate-to-vigorous PA (p-interaction = 0.13) and step count (p-interaction = 0.18) did not differ between groups.
CONCLUSION: The remote booster program effectively reduced ST and increased light PA in CAD patients. These findings highlight the potential to change physical (in)activity behaviour of patients beyond completion of traditional CR programs.
TRIAL REGISTRATION: NCT06038188 (ClinicalTrials.gov).